Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 24, 2013

Primary Completion Date

September 30, 2032

Study Completion Date

September 30, 2032

Conditions

X-Linked Chronic Granulomatous Disease

Interventions

GENETIC

X vivo gene therapy

Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene

Trial Locations (2)

University College London Hospital (UCLH), London

Great Ormond Street Hospital NHS Foundation Trust, London